D. Bilton (London, United Kingdom), J.S. Elborn (Belfast, United Kingdom), L. Hansson (Lund, Sweden), H. Heijerman (The Hague, The Netherlands)
Evaluation of annual FEV1 decline and factors associated with its accelerated deterioration in a cohort of adults with cystic fibrosis
B. P. Dubé, M. S-Carricart, J. Lévesque, C. Poirier (Montreal, Canada)
|  |
Biomarkers of early relapse of pulmonary exacerbation in cystic fibrosis adult patients
L. C. Morlacchi, V. Rosti, R. Elia, M. Mantero, B. Dallari, S. Galbiati, M. Zanardelli, A. D'Adda, F. Blasi, G. Pizzamiglio (Milano, Milan, Italy)
|  |
Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
I. Sequeiros, N. Jarad (Bristol, United Kingdom)
| |
Metabolic and respiratory functioning of patients with cystic fibrosis during the years preceding death
T. Kalami, K. Williams, K. Pollard, P. Whitaker, D. Peckham (Leeds, United Kingdom)
| |
Predicting five year outcomes in adults with cystic fibrosis: Developing a predictive scoring model
L. Clarke, K. Oates, C. Haworth, J. Elliott, A. Floto (Cambridge, United Kingdom)
| |
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
C. Green, A. Y. H. Lim (Stoke on Trent, United Kingdom; Singapore, Singapore)
| |
Possible role of liver disease and respiratory insufficiency in osteopenia in cystic fibrosis patients
B. Godbert, S. Montcouquiol, A. C. Rat, M. Yves (Metz, Vandoeuvre-les-Nancy, France)
| |
Bone turnover markers and vitamin D status in patients with cystic fibrosis
T. Jakovska-Maretti, J. Meceska-Jovcevska, S. Fustik, L. Spirevska (Skopje, Fyrom)
| |
Lung function and early abnormality of glucose tolerance (GT) in cystic fibrosis (CF) patients
A. Leclercq, L. Kessler, V. Rosner, L. Weiss, B. Gauthier, R. Kessler (Strasbourg, Reims, France)
| |
Incidence and prevalence of non tuberculous mycobacteria [NTM] in adult CF population: A large adult CF centre experience
A. Kumar, C. Etherington, D. G. Peckham (Leeds, United Kingdom)
| |
Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease
B. Godbert, A. Briault (Metz, Vandoeuvre-les-Nancy, France)
| |
Retrospective cohort study of adult cystic fibrosis patients colonised with achromobacter Xylosoxidans
J. Robson, C. Etherington, D. Peckham (Leeds, United Kingdom)
| |
Eradication regime of methicillin resistant staphylococcus aureus lung infection in cystic fibrosis
S. Fustik, T. Jakovska, L. Spirevska (Skopje, Fyrom)
| |
The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
C. Orchard, S. Srivastava, J. Burgess, N. Simmonds, D. Bilton, E. H. Baker (London, United Kingdom)
| |
The impact of genotype on clinical course of cystic fibrosis (CF) in adult patients
S. Krasovskij, E. Amelina, V. Samoylenko, N. Petrova, A. Stepanova, A. Polyakov, M. P. Audrézet, C. Férec, M. Usacheva (Moscow, Russian Federation; Brest, France)
| |
Fatigue in cystic fibrosis: A novel prospective study investigating subjective and objective factors associated with fatigue
N. Jarad, I. Sequeiros, P. Patel, K. Bristow, Z. Sund (Bristol, United Kingdom)
| |
Clinical features of adult’s cystic fibrosis in the Republic of Belarus
N. Manovitskaya, H. Baradzina (Minsk, Belarus)
| |